OncoMatch/Clinical Trials/NCT05276726
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Is NCT05276726 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies JAB 21822 for non-small cell lung cancer.
Treatment: JAB 21822 — Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KEAP1 wild-type
Required: KRAS p.g12c
Required: STK11 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Exception: within 3 weeks of study day 1
Therapeutic radiation therapy within 3 weeks of study day 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05276726 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Does this trial require KEAP1?
Yes, KEAP1 wild-type is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS p.g12c is a required biomarker for enrollment.
Does this trial require STK11?
Yes, STK11 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages